NCT07047209 - Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Interventions

DRUG

Digoxin

Digoxin tablets will be administered orally in a once daily dosage. Each tablet is scored and is of 125 mcg strength. Participants will take 1 tablet, two tablets or half a tablet depending on the dosing tier they are in during study participation.

Trial Locations (3)

33314

RECRUITING

Nova Southeastern University, Davie

60611

RECRUITING

Northwestern Universsity, Chicago

02114

RECRUITING

MGH, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER